Pharma Focus Asia

Inventiva and Hepalys Pharma Announce Licence Agreement to Commercialize Lanifibranor

Thursday, September 21, 2023

Inventiva announced an exclusive licencing agreement with Hepalys Pharma, aimed at the development and commercialisation of promising drug candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH) in the important markets of Japan and South Korea.

Under this exclusive licencing agreement, Inventiva will receive an upfront payment of $10 million. In addition to this initial sum, there is the potential for milestone payments, totalling up to $231 million, contingent upon successful progress in clinical development, regulatory approvals, and commercialisation efforts. Furthermore, tiered royalties will be received, ranging from the mid double digits to the low twenties, based on net sales of lanifibranor in Japan and South Korea.

This collaboration represents a significant milestone for Inventiva to expand its global footprint, reaching into the key markets of Japan and South Korea. This agreement, accelerates the potential commercialisation of lanifibranor in these two major territories. Moreover, this partnership remains committed to advancing lanifibranor as a potential solution for NASH patients in Japan and South Korea.

Lanifibranor is an orally-administered small molecule designed to induce a range of therapeutic effects in the body, including anti-fibrotic, anti-inflammatory, and beneficial changes in vascular and metabolic functions. It accomplishes these effects by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms. These PPARs are well-known nuclear receptor proteins responsible for regulating gene expression.

Unlike other PPAR agonists that selectively target one or two isoforms, lanifibranor's broad-spectrum activation offers a promising approach to comprehensively address the complex aspects of NASH and its associated complications.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference